KALA BIO

What KALA BIO does

KALA BIO, Inc. (NASDAQ: KALA) is a public biopharmaceutical company headquartered in Arlington, Massachusetts, that has pivoted from a clinical-stage drug developer focused on mesenchymal stem cell secretome (MSC-S) therapies for ocular diseases into a dual-engine growth company combining its legacy drug pipeline with an enterprise AI infrastructure platform. The company's historical core technology was the MSC-S platform, including the lead asset KPI-012 for persistent corneal epithelial defect (PCED), which was acquired via the 2021 purchase of Combangio but failed to meet its primary clinical endpoint in 2025. Following this setback, KALA BIO entered into an exclusive worldwide license with Younet AI in March 2026 for the Researgency AI research platform and commercially launched the Bionic Intelligence Research Agent (BIRA), an autonomous AI agent powered by a 70-billion-parameter large language model (Researgent 2.0) trained on biotech and healthcare datasets.

The Researgency.ai platform is designed for on-premises deployment within VPN-secured, client-controlled environments, targeting enterprise biotech and pharmaceutical companies that require data sovereignty over proprietary biological data. The company positions the platform for research intelligence, clinical trial planning, protocol optimization, regulatory compliance monitoring, and scenario modeling workflows. KALA BIO's business model combines recurring platform-as-a-service subscription licensing for the AI platform with legacy biopharmaceutical drug development economics. As of late 2025, the company had one named external customer (Red Light Holland, supporting Filament Health's PEX010 psilocybin program) and a small headcount of 11-50 employees. Leadership transitioned in December 2025 with David E. Lazar appointed CEO and Chairman through a $6M securities purchase agreement, and the company has raised approximately $22M+ across multiple financing rounds in late 2025 and early 2026 while settling $10.6M in Oxford Finance debt and executing a 1-for-50 reverse stock split in May 2026 to maintain Nasdaq listing.

Name

KALA BIO

Legal name

KALA BIO, Inc.

Website

https://kalarx.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

KALA BIO is a publicly traded biopharmaceutical company (NASDAQ: KALA) that operates an on-premises AI research platform (Researgency.ai with BIRA agent) for biotech and pharmaceutical clients, alongside a legacy pipeline of mesenchymal stem cell secretome therapies for ocular diseases. It serves enterprise biopharma organizations seeking data-sovereign AI infrastructure.

Ownership category

akta.pro rank

Product category

Biopharma AI Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Biopharma AI platform
• Agentic AI biotech
• Clinical trial data analytics
• On-premises AI infrastructure
• Ophthalmic secretome therapy

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform-as-a-Service Licensing: Recurring subscription-based licensing of Researgency.ai AI infrastructure platform to external biotech and pharmaceutical companies. Enterprise clients deploy on-premises AI systems within their own environments.
2. AI Platform Services: Revenue generated from deployment of Researgency.ai platform for clinical development support, planning, protocol optimization, and scenario modeling for biotech clients.
3. Drug Development and Commercialization: Traditional biopharmaceutical revenue model through development and commercialization of therapeutic candidates including KPI-012 for persistent corneal epithelial defect (PCED) and other rare eye disease treatments.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

KALA BIO develops and deploys Researgency.ai, an enterprise on-premises agentic AI platform for biopharmaceutical research, along with its Bionic Intelligence Research Agent (BIRA) powered by a 70-billion-parameter large language model. The company also retains a legacy drug pipeline built on its mesenchymal stem cell secretome (MSC-S) platform, including the KPI-012 candidate for persistent corneal epithelial defect (PCED).

Product overview

KALA BIO is pivoting from a single-pipeline clinical-stage biopharmaceutical company focused on mesenchymal stem cell secretome (MSC-S) therapies for eye diseases into a dual-engine growth company combining its legacy drug pipeline with an enterprise AI infrastructure platform. The core products are Researgency.ai (an on-premises AI platform for biotech and pharma) and the Bionic Intelligence Research Agent (BIRA) deployed within it, alongside legacy programs including KPI-012 (MSC-S therapy for persistent corneal epithelial defect) and the underlying MSC-S technology platform.

Differentiator

Problem solved

Functional benefit

Brands

• Researgency.ai: Enterprise AI platform for biopharmaceutical research, providing on-premises agentic AI solutions for biotech and pharmaceutical companies to analyze clinical trial data.

Products and services

• Researgency.ai An enterprise on-premises AI infrastructure platform for the biotechnology and pharmaceutical industry that enables secure deployment of AI agents within client-controlled environments so proprietary biological data never leaves the client's control. Operates on a platform-as-a-service subscription model for enterprise biotech and pharma research, clinical trial, regulatory, and commercial launch workflows.
• Bionic Intelligence Research Agent (BIRA) An autonomous agentic AI product deployed through the Researgency.ai platform, powered by Researgent 2.0, a 70-billion-parameter large language model trained on biotech and healthcare datasets. Designed for research intelligence, clinical trial documentation, regulatory compliance monitoring, safety monitoring, and commercial launch workflows within VPN-secured client environments.
• KPI-012 A novel mesenchymal stem cell secretome (MSC-S) therapy candidate for persistent corneal epithelial defect (PCED), a rare ocular condition. Acquired via the Combangio transaction and previously advanced through Phase 1b clinical trials for patients with severe ocular surface diseases.
• MSC-S Platform KALA BIO's proprietary mesenchymal stem cell secretome therapy platform historically focused on treatments for severe ocular surface diseases. The platform's research data also serves as the first deployment environment and training context for the Researgency.ai AI platform.

Quantifiable outcome

• Platform designed to generate recurring revenue through platform-as-a-service subscription model
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

• Red Light HollandflagshipStrategic or Co-development Partner · 18 March 2026First external deployment client for Researgency.ai platform. Engaged to support clinical development of Filament Health's PEX010 botanical psilocybin drug candidate using AI platform for planning, protocol optimization, and scenario modeling as part of broader strategic move following Red Light Holland's acquisition of Filament.
• Younet AI (2624465 Ontario Inc.)coreTechnology or Integration · 3 March 2026Platform Development and Exclusive License Agreement signed March 3, 2026 for exclusive worldwide rights to deploy Researgency AI research platform in biotechnology field. Initial 12-month term with renewal options. KALA will pay up to $530,000 in cash and issue 5,000,000 shares of common stock to Younet, with an irrevocable option to acquire Younet for $55,000,000.
• Filament Health Corp.minorStrategic or Co-development PartnerPEX010 botanical psilocybin drug candidate being developed with clinical support from Researgency.ai platform. Red Light Holland engaged KALA's platform specifically for Filament's drug candidate development.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Owkin: AI platform for biomedical research with federated learning and on-premises deployment to address data sovereignty — closely paralleling Researgency.ai's positioning for pharma and academic medical centers.
• BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to surface therapeutic hypotheses. Comparable as an AI-platform-for-pharma peer, though more drug-asset-oriented than platform-license-oriented.
• Insilico Medicine: AI-driven drug discovery company with proprietary platforms for target identification and generative chemistry. Comparable to Researgency.ai's AI-for-biotech mission, though more discovery-stage than platform-stage.

Direct peers

• Recursion Pharmaceuticals: AI-native biotech combining proprietary data generation with ML models for drug discovery. Comparable to Researgency.ai as an AI-platform-for-biotech peer, though Recursion is also an asset owner rather than pure platform.
• Schrödinger, Inc. Publicly traded AI-driven computational drug discovery platform serving biotech and pharma. Closest direct comparable to Researgency.ai by virtue of selling software/informatics to the same enterprise biotech buyer with a subscription + services model.
• AbCellera Biologics: AI-enabled antibody discovery platform combining wet-lab screening with ML. Comparable to Researgency.ai as a tech-forward, AI/ML-enabled discovery platform serving biotech and pharma customers.

Broad incumbents

• Ginkgo Bioworks: Large platform biotech providing organism engineering and biosecurity infrastructure. Overlaps with Researgency.ai as a 'platform-as-a-service' biotech vendor but at much larger scale and focused on synthetic biology rather than drug discovery workflows.
• Palantir Technologies: Enterprise data analytics platform explicitly cited in KALA's positioning as 'the Palantir for biotech.' Comparable as an on-premises/sovereign-data enterprise AI vendor, though operating across many verticals beyond life sciences.
• Tempus AI: Larger AI-enabled healthcare data and analytics platform. Overlaps with Researgency.ai on AI infrastructure for life sciences but operates at much greater scale and across clinical/oncology data rather than discovery workflows.

Others

• Aerie Pharmaceuticals: Specialty ophthalmology biopharma historically focused on ocular surface and glaucoma therapeutics. Comparable to KALA's legacy MSC-S/eye-disease franchise rather than to the AI platform, useful for benchmarking the discontinued therapeutic direction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kala-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds17 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KALA BIO